公开(公告)号：US09650633B2

公开(公告)日：2017-05-16

申请号：US14778600

申请日：2014-11-03

Applicant: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Daeyoup Lee ,  Seung-Kyoon Kim ,  Hosuk Lee

IPC: C12N15/113 ,  C07K16/00 ,  C12N5/0735 ,  C07K16/18 ,  C12N15/115

CPC classification number: C12N15/113 ,  C07K16/18 ,  C07K2317/76 ,  C12N5/0606 ,  C12N15/1137 ,  C12N15/115 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/16 ,  C12N2320/30 ,  C12Y201/01043

Abstract: Provided is a composition for controlling pluripotency of stem cells including an LIN28A methylation inhibitor and a screening method of the LIN28A methylation inhibitor, and more particularly, a composition for controlling pluripotency of stem cells including an inhibitor controlling methylation of 135th lysine of LIN28A that is methylated by SET7/9, or a composition for treating cancer, and a screening method of the inhibitor, wherein the screening method includes (a) contacting a candidate material with a cell, the cell having a gene introduced thereinto; (b) measuring a methylation level of the 135th lysine of the LIN28A; and (c) selecting an inhibitor controlling methylation of the 135th lysine of the LIN28A. That is, the present invention relates to a composition for controlling pluripotency of embryonic stem cells, or an anti-cancer composition, and a screening method of the inhibitor. The method of the present invention is possible to screen materials capable of controlling pluripotency of embryonic stem cells or materials having anti-cancer activity, and the materials screened by the method of the present invention may control pluripotency of embryonic stem cells and inhibit growth of cancer cells, which is effective for disorders of stem cell differentiation or preparation of cancer therapeutic agents.

公开(公告)号：US20170058271A1

公开(公告)日：2017-03-02

申请号：US15249756

申请日：2016-08-29

Applicant: The General Hospital Corporation

Inventor： J. Keith Joung ,  Benjamin Kleinstiver ,  Vikram Pattanayak

IPC: C12N9/22 ,  C12N15/90

CPC classification number: C12N9/22 ,  C07K2319/00 ,  C07K2319/71 ,  C12N9/16 ,  C12N15/90 ,  C12N15/902 ,  C12N15/907 ,  C12N2800/22 ,  C12Y114/11 ,  C12Y201/01043 ,  C12Y203/01048 ,  C12Y301/00 ,  C12Y305/01098

Abstract: Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenotnic engineering, genome targeting, and genome editing.

Abstract translation: 具有改进的特异性及其在基因组工程，表观遗传学工程，基因组靶向和基因组编辑中的应用的工程化CRISPR-Cas9核酸酶。

公开(公告)号：US20170044550A1

公开(公告)日：2017-02-16

申请号：US15265104

申请日：2016-09-14

Applicant: The General Hospital Corporation

Inventor： Jeannie T. Lee ,  Jing Zhao ,  Kavitha Sarma ,  Mark Borowsky ,  Toshiro Kendrick Ohsumi

IPC: C12N15/113 ,  C12Q1/68

CPC classification number: C12N15/1137 ,  A61K9/1271 ,  A61K31/713 ,  C12N15/113 ,  C12N15/1135 ,  C12N15/1136 ,  C12N2310/113 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/314 ,  C12N2310/315 ,  C12N2310/3181 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/346 ,  C12N2320/30 ,  C12N2320/32 ,  C12N2330/31 ,  C12Q1/6876 ,  C12Q1/6881 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/178 ,  C12Y201/01043

Abstract: This invention relates to long non-coding RNAs (lncRNAs), libraries of those lncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting lncRNAs.

Abstract translation: 本发明涉及长非编码RNA（lncRNA），结合染色质修饰剂的那些lncRNA的文库，例如Polycomb Repressive Complex 2，抑制性核酸和用于靶向lncRNA的方法和组合物。

公开(公告)号：US20160355806A1

公开(公告)日：2016-12-08

申请号：US15050273

申请日：2016-02-22

Applicant: The General Hospital Corporation

Inventor： Jeannie T. Lee ,  Jing Zhao ,  Kavitha Sarma ,  Mark Borowsky ,  Toshiro Kendrick Ohsumi

IPC: C12N15/113 ,  C12Q1/68

CPC classification number: C12N15/1137 ,  A61K9/1271 ,  A61K31/713 ,  C12N15/113 ,  C12N15/1135 ,  C12N15/1136 ,  C12N2310/113 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/314 ,  C12N2310/315 ,  C12N2310/3181 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/346 ,  C12N2320/30 ,  C12N2320/32 ,  C12N2330/31 ,  C12Q1/6876 ,  C12Q1/6881 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/178 ,  C12Y201/01043

Abstract: This invention relates to long non-coding RNAs (lncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting lncRNAs.

Abstract translation: 本发明涉及长非编码RNA（lncRNA），结合染色质修饰剂的那些ncRNA的文库，例如Polycomb Repressive Complex 2，抑制性核酸以及用于靶向lncRNA的方法和组合物。

公开(公告)号：US20160137989A1

公开(公告)日：2016-05-19

申请号：US15003174

申请日：2016-01-21

Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

Inventor： Ming-ming Zhou ,  Shiraz Mujtaba

IPC: C12N9/10

CPC classification number: C12N9/1007 ,  A61K38/00 ,  A61K38/43 ,  A61K48/00 ,  C07K14/005 ,  C07K2319/09 ,  C12N2710/00022 ,  C12N2710/10343 ,  C12N2740/15043 ,  C12Y201/01043

Abstract: The present invention relates to methods of suppressing the transcriptional expression of one or more genes by methylating the chromatin histone proteins of the one or more genes. Specifically, a viral SET domain histone lysine methyltransferase (vSET or vSET-like protein) methylates lysine 27 of a gene's histone protein 3 (H3-K27) thereby suppressing the transcription of the gene.

Abstract translation: 本发明涉及通过甲基化一种或多种基因的染色质组蛋白蛋白来抑制一种或多种基因的转录表达的方法。 具体地，病毒SET结构域组蛋白赖氨酸甲基转移酶（vSET或vSET样蛋白）甲基化基因的组蛋白3（H3-K27）的赖氨酸27，从而抑制基因的转录。

公开(公告)号：US20140161785A1

公开(公告)日：2014-06-12

申请号：US14098797

申请日：2013-12-06

Applicant: Feiyan Liu ,  Ping Wu ,  Kebin Liu

Inventor： Feiyan Liu ,  Ping Wu ,  Kebin Liu

IPC: A61K31/548 ,  C12N9/99 ,  A61K45/06

CPC classification number: A61K31/548 ,  A61K45/06 ,  C12N9/1007 ,  C12Y201/01043 ,  A61K2300/00

Abstract: Verticillin A is found to be a potent inhibitor of histone methyltransferases, selective for G9a, GLP, SUV39H1, SUV39H2, MLL1, and NSD2. Methods of using Verticillin A are provided. The Verticillin A can be synthetically produced or it can be isolated from natural sources. Methods if inhibiting one or more histone methyltransferases are provided. In addition, methods are provided for treating diseases or disorders related to overexpression of one or more histone methyltransferases. Exemplary diseases and disorders to be treated include cancer, asthma, HIV, and progeria.

Abstract translation: 发现秋水仙素A是对G9a，GLP，SUV39H1，SUV39H2，MLL1和NSD2有选择性的组蛋白甲基转移酶的有效抑制剂。 提供了使用秋水仙素A的方法。 秋水仙素A可以合成生产，也可以从天然来源分离。 抑制一种或多种组蛋白甲基转移酶的方法。 此外，提供了用于治疗与一种或多种组蛋白甲基转移酶的过表达相关的疾病或病症的方法。 待治疗的示例性疾病和病症包括癌症，哮喘，HIV和progeria。

公开(公告)号：US20130203625A1

公开(公告)日：2013-08-08

申请号：US13817812

申请日：2011-08-18

Applicant: Ryuji Hamamoto ,  Yusuke Nakamura ,  Takuya Tsunoda

Inventor： Ryuji Hamamoto ,  Yusuke Nakamura ,  Takuya Tsunoda

IPC: G01N33/50 ,  C12Q1/68 ,  C12Q1/48 ,  G01N33/68

CPC classification number: G01N33/5011 ,  A61K31/713 ,  C12N15/1137 ,  C12N2310/14 ,  C12Q1/48 ,  C12Q1/6897 ,  C12Y201/01043 ,  G01N33/57407 ,  G01N33/6872 ,  G01N2500/04

Abstract: The present invention relates to the roles played by the SUV420H1 and SUV420H2 genes in carcinogenesis and features a method for treating or preventing cancer by administering a double-stranded molecule against the SUV420H1 or SUV420H2 gene or a composition or vector containing such a double-stranded molecule. The present invention also features methods and kits for detecting or diagnosing cancer in a subject, including detecting an expression level of the SUV420H1 or SUV420H2 gene. The present invention further features methods and kits for assessing or determining the prognosis of a subject with cancer, including detecting the expression level of an SUV420H2 gene. Also, disclosed are methods of screening for candidate substances for treating or preventing cancer or inhibiting cancer cell growth, using as an index their effect on the expression or activity of SUV420H1 or SUV420H2.

Abstract translation: 本发明涉及SUV420H1和SUV420H2基因在癌发生中的作用，其特征在于通过对SUV420H1或SUV420H2基因施用双链分子或含有这种双链分子的组合物或载体来治疗或预防癌症的方法 。 本发明还特征在于检测或诊断受试者的癌症的方法和试剂盒，包括检测SUV420H1或SUV420H2基因的表达水平。 本发明还涉及用于评估或确定患有癌症的受试者的预后的方法和试剂盒，包括检测SUV420H2基因的表达水平。 此外，公开了使用作为SUV420H1或SUV420H2的表达或活性的指标作为指标来筛选用于治疗或预防癌症或抑制癌细胞生长的候选物质的方法。

公开(公告)号：US20110123511A1

公开(公告)日：2011-05-26

申请号：US12896510

申请日：2010-10-01

Applicant: MING-MING ZHOU ,  SHIRAZ MUJTABA

Inventor： MING-MING ZHOU ,  SHIRAZ MUJTABA

IPC: A61K38/45 ,  C12N5/02 ,  A61K48/00

CPC classification number: C12N9/1007 ,  A61K38/00 ,  A61K48/00 ,  C07K14/005 ,  C07K2319/09 ,  C12N2710/00022 ,  C12N2710/10343 ,  C12N2740/15043 ,  C12Y201/01043

Abstract: The present invention relates to methods of suppressing the transcriptional expression of one or more genes by methylating the chromatin histone proteins of the one or more genes. Specifically, a viral SET domain histone lysine mehtyltransferase (vSET or vSET-like protein) methylates lysine 27 of a gene's histone protein 3 (H3-K27) thereby suppressing the transcription of the gene.

Abstract translation: 本发明涉及通过甲基化一种或多种基因的染色质组蛋白蛋白来抑制一种或多种基因的转录表达的方法。 具体地，病毒SET结构域组蛋白赖氨酸甲酰转移酶（vSET或vSET样蛋白）甲基化基因的组蛋白3（H3-K27）的赖氨酸27，从而抑制基因的转录。

公开(公告)号：US20050266473A1

公开(公告)日：2005-12-01

申请号：US11140659

申请日：2005-05-27

Applicant: Yi Zhang ,  Ru Cao

Inventor： Yi Zhang ,  Ru Cao

IPC: C07H21/04 ,  C12N5/06 ,  C12N9/00 ,  C12N9/10 ,  C12N9/16 ,  C12P21/06 ,  C12Q1/68

CPC classification number: C12N9/1007 ,  C07K14/82 ,  C07K2319/20 ,  C12N2799/026 ,  C12Y201/01043 ,  G01N2333/91011

Abstract: The present invention provides a reconstituted complex including EED, EZH2 and SUZ12 wherein the reconstituted complex has histone methyltransferase (HMTase) activity for lysine 27 of histone H3 (H3-K27). The reconstituted complex may further include RbAp48, AEBP2 or both. Also disclosed are methods of producing the reconstituted complex, methods of identifying compounds that inhibit the HTMase activity of the reconstituted complex and methods of identifying candidate compounds for treating cancer. Reagents and kits including the reconstituted complex are further provided.

Abstract translation: 本发明提供了包含EED，EZH2和SUZ12的复原复合物，其中重构的复合物对组蛋白H3（H3-K27）的赖氨酸27具有组蛋白甲基转移酶（HMTase）活性。 重构的复合物还可以包括RbAp48，AEBP2或两者。 还公开了生产重建复合物的方法，鉴定抑制重构复合物的HTMase活性的化合物的方法和鉴定用于治疗癌症的候选化合物的方法。 还提供了试剂和试剂盒，包括重构的复合物。

公开(公告)号：US20240125783A1

公开(公告)日：2024-04-18

申请号：US18491255

申请日：2023-10-20

Applicant: California Institute of Technology

Inventor： Mitchell Guttman ,  Mario R. Blanco ,  Ward Walkup, IV

IPC: G01N33/573 ,  C12N15/90

CPC classification number: G01N33/573 ,  C12N15/907 ,  C12Y201/01043

Abstract: In some embodiments, methods of detecting an association between a query protein and a target moiety are described. In some embodiments, compositions are described. In some embodiments, kits are described.